Sandler R M, Seifer D B, Morgan K, Pockros P J, Wypych J, Weiss L M, Schiffman S
Am J Clin Pathol. 1985 Jun;83(6):760-4. doi: 10.1093/ajcp/83.6.760.
A 46-year-old female who died as a result of thrombocytopenia associated with multiple arterial occlusions and septicemia while on heparin therapy was found to have a platelet-aggregating factor present in several plasma samples and in a sample of serum. This factor was subsequently shown to be an IgG with aggregating properties toward normal platelets that were enhanced by, but not dependent on, the presence of heparin. Further studies showed that heparin was unlikely to have acted as a hapten in initiating the IgG production but that its role was significant in aggravating the ensuing arterial thrombosis. The necessity of substitution of heparin with alternative anticoagulant/antithrombotic therapy to avoid the worst sequelae of this potentially catastrophic syndrome is discussed.
一名46岁女性在接受肝素治疗时因血小板减少症合并多处动脉闭塞和败血症死亡,在其多个血浆样本和一份血清样本中发现了一种血小板聚集因子。随后证明该因子是一种IgG,对正常血小板具有聚集特性,肝素的存在可增强这种特性,但并非依赖于肝素。进一步研究表明,肝素不太可能作为半抗原引发IgG产生,但其在加重随后的动脉血栓形成中起重要作用。讨论了用替代抗凝/抗血栓治疗替代肝素以避免这种潜在灾难性综合征最严重后果的必要性。